TLR receptors in laryngeal carcinoma - immunophenotypic, molecular and functional studies

Folia Histochemica et Cytobiologica

Volumn 48, Issue 4, 2010, Pages 624-631

  Sikora, Jan ^a   Frydrychowicz, Magdalena ^a   Kaczmarek, Mariusz ^a   Brzezicha, Bartosz ^a   Mozer Lisewska, Iwona ^a   Szczepański, Miroslaw ^a   Zeromski, Jan ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cell culture; Cell lines; Flow cytometry; Laryngeal carcinoma; RT PCR; Toll like receptors

Indexed keywords

MESSENGER RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ARTICLE; CARCINOMA CELL; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING; LARYNX CARCINOMA; MOLECULAR BIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA ANALYSIS;

EID: 79958050944     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.2478/v10042-010-0077-0     Document Type: Article

References (27)

1. Chen R, Alvero AB, Silasi DA et al. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol. 2007;57:93-107.
2. Beutler BA. TLRs and innate immunity. Blood. 2009;113; 1399-1407.
3. Chen K, Huang J, Gong W et al. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol. 2007; 7:1271-1275.
4. Balogh S, Kiss I, Csaszar A. Toll-like receptors: link between "danger" signals and plaque instability. Curr Drug Targets. 2009;6:513-518.
5. Knol AC, Ehst BD, Dompmartin A et al. Toll-like receptor 2, 4 and 9 expression in primary cutaneous CD30+ T-cell lymphoma. Br J Dermatol. 2009;161:1414-1426.
6. Etokebe GE, Knezevic J, Petricevic B et al. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4 in case-control study with breast cancer. Genet Test Mol Biomarkers. 2009;13:729-734.
7. Droemann D, Albrecht D, Gerdes J et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res. 2005;6:1-10.
8. Tang XY, Zhu YQ, Wei B, Wang H. Expression and functional research of TLR4 in human colon carcinoma. Am J Med Sci. 2010;339:319-326.
9. Chang S, Kodys K, Szabo G. Impaired expression and function of Toll-like receptor 7 in hepatitis C virus infection In human hepatoma. Hepatology. 2010;51:35-42.
10. Szajnik M, Szczepanski MJ, Czystowska M et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28:4353-4363.
11. Zeromski J, Mozer-Lisewska I, Kaczmarek M. Significance of Toll-like receptors expression in tumor growth and spreading: a short review. Cancer Microenvironment. 2008;1:37-42.
12. Tillman DK Jr, Caroll MT. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience. Cutis. 2007;79:241-248.
13. Carneiro RC, de Macedo EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular basal cell carcinoma. Ophtal Plas Reconstr Surg. 2010;26:100-102.
14. Huang SJ, Hijnen D, Murphy GF et al. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009;129:2676-2685.
15. Kundu SD, Lee C, Billips BK et al. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate. 2008;68:223-229.
16. Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol. 2007;57:93-107.
17. Szczepański M, Stelmachowska M, Stryczyński L. et al. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otolaryngol. 2007;264:525-530.
18. Lin CJ, Grandis JR, Carey TE et al. Head and neck squamous carcinoma cell lines: established models and rationale for selection. Head & Neck. 2007;29:163-188.
19. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head & Neck. 2001;23:147-158.
20. Verastegui E, Morales R, Barrera JL et al. Immunological approach in the evaluation of regional lymph nodes of patients with squamous carcinoma of the head and neck. Clin Immunol. 2002;102:37-47.
21. Lemaitre B, Nicolas E, Michaut L et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86:973-983.
22. Kundu SD, Lee C, Billips BK et al. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate. 2008;68:223-229.
23. Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol. 2007;57:93-107.
24. Szczepanski MJ, Czystowska M, Szajnik M et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009;69:3105-3113.
25. Rydberg C, Mansson A, Uddman R et al. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunology. 2009;128(1 suppl):e600-611.
26. O'Neill LAJ. TLRs play good cop, bad cop in the lung. Nature Medicine. 2005;11:1161-1162.
27. Adams S, O'Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol. 2008;181:776-784.